Companies / United Kingdom
OTC Orlistat Is Approvable
April 2006 | Company Finance AlertThe FDA has designated UK drugmaker GlaxoSmithKline (GSK)'s Alli - the over-the-counter version of Switzerland-based Roche's Xenical (orlistat) - as approvable, enabling registration and launch later this year. If Alli receives approval, it will become the first lipase inhibitor to attain non-prescription status. The product is forecast to cost between US$12 and US$25, and patients are recommended to take the drug for only 6 months. GSK estimates that 5 million patients would buy the product, resulting in revenue in the region of
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
